BCRX Q2 2024 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$109M+32.5% YoY

Gross Profit

$108M98.4% margin

Operating Income

$9M8.0% margin

Net Income

-$13M-11.6% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+17.9%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$2M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$472M

Total Liabilities

$948M

Stockholders' Equity

-$476M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$109M	$82M	+32.5%
Gross Profit	$108M	$82M	+32.0%
Operating Income	$9M	-$21M	+142.3%
Net Income	-$13M	-$75M	+83.2%

Revenue Segments

Product

$108M99%

Collaborative and Other Research and Development

$1M1%